Person:

Show:

Publications

Footer

Operated by

University of Münster
Division 6.4: Research Information Management
Department 6: Research Affairs
Domplatz 6-7 | 48143 Münster
cris@uni-muenster.de

Top-Links

About the University of Münster
Research profile of the University of Münster
CRIS-Login

living.knowledge

Legal Disclosure | Privacy Statement | Accessibility

Angenendt, Linus

Deep learning predicts therapy-relevant genetics in acute myeloid leukemia from Pappenheim-stained bone marrow smears Kockwelp, Jacqueline; Thiele, Sebastian; Bartsch, Jannis; Haalck, Lars; Gromoll, Jörg; Schlatt, Stefan; Exeler, Rita; Bleckmann, Annalen; Lenz, Georg; Wolf, Sebastian; Steffen, Björn; Berdel, Wolfgang Eduard; Schliemann, Christoph; Risse, Benjamin; Angenendt, Linus (2024) In: Blood Advances, 8(1), 70-79. doi:10.1182/bloodadvances.2023011076 Research article (journal) \| Peer reviewed \| Published
Cell Selection-based Data Reduction Pipeline for Whole Slide Image Analysis of Acute Myeloid Leukemia Kockwelp, Jacqueline; Thiele, Sebastian; Kockwelp, Pascal; Bartsch, Jannis; Schliemann, Christoph; Angenendt, Linus; Risse, Benjamin (2022) In: IEEE/CVF (eds.), The IEEE / CVF Computer Vision and Pattern Recognition Conference (CVPR). IEEE Xplore. Research article in digital collection (conference) \| Peer reviewed \| Published
563P First-in-class CD13-targeted tissue factor tTF-NGR in patients with recurrent or refractory malignant tumours: Safety and pharmacokinetic results of a phase I study Schliemann C, Gerwing M, Heinzow H, Harrach S, Schwöppe C, Wildgruber M, Hansmeier AA, Angenendt L, Berdel AF, Kessler T, Wilms C, Hartmann W, Wardelmann E, Krähling T, Heindel W, Gerss J, Schmidt H, Lenz G. Mesters R, Berdel WE (2020) In: (eds.), . (kein Verlag angegeben). Research article in edited proceedings (conference) \| Peer reviewed \| Published
First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study Schliemann C, Gerwing M, Heinzow H, Harrach S, Schwöppe C, Wildgruber M, Hansmeier AA, Angenendt L, Berdel AF, Stalmann U, Berning B, Kratz-Albers K, Middelberg-Bisping K, Wiebe S, Albring J, Wilms C, Hartmann W, Wardelmann E, Krähling T, Heindel W, Gerss J, Bormann E, Schmidt H, Lenz G, Kessler T, Mesters RM, Berdel WE (2020) In: Cancers, 12(6). doi:10.3390/cancers12061488 Research article (journal) \| Peer reviewed \| Published
NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor Brand C., Schliemann C., Ring J., Kessler T., Bäumer S., Angenendt L., Mantke V., Ross R., Hintelmann H., Spieker T., Wardelmann E., Mesters R., Berdel W., Schwöppe C. (2016) In: Oncotarget, 7(6), 6774-6789. doi:10.18632/oncotarget.6725 Research article (journal) \| Peer reviewed \| Published
A phase i dose escalation study of the triple angiokinase inhibitor nintedanib combined with low-dose cytarabine in elderly patients with acute myeloid leukemia In: . \| Peer reviewed
Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation In: , -. \| Peer reviewed
Remissions of different quality following rituximab, tocilizumab and rituximab, and allogeneic stem cell transplantation in a patient with severe idiopathic multicentric Castleman’s disease In: , -. \| Peer reviewed
Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature In: , -. \| Peer reviewed
Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation In: , -. \| Peer reviewed

Schliemann C., Gerss J., Wiebe S., Mikesch J., Knoblauch N., Sauer T., Angenendt L., Kewitz T., Urban M., Butterfass-Bahloul T., Edemir S., Vehring K., Müller-Tidow C., Berdel W., Krug U.

(2016)

PloS one

, 11

(10)

doi:10.1371/journal.pone.0164499

Research article (journal)

| Published

Angenendt L, Schliemann C, Lutz M, Rebber E, Schulze AB, Weckesser M, Stegger L, Schäfers M, Groth C, Kessler T, Lenz G, Stelljes M, Berdel WE

(2016)

Bone Marrow Transplantation

, 51

(3)

443

445

doi:10.1038/bmt.2015.266

Research article (journal)

| Published

Angenendt L., Kerkhoff A., Wiebe S., Mikesch J., Rudat A., Wötzel F., Wenning C., Schliemann C., Kessler T., Schäfers M., Wardelmann E., Stelljes M., Berdel W.

(2015)

Annals of Hematology

, 94

(7)

1241

1243

doi:10.1007/s00277-015-2353-8

Research article (journal)

| Published

Börschel N., Schwöppe C., Zerbst C., Angenendt L., Kessler T., Klapper W., Giovannoni L., Elia G., Neri D., Berdel W., Mesters R., Schliemann C.

(2015)

Leukemia Research

, 39

(7)

739

748

doi:10.1016/j.leukres.2015.04.005

Research article (journal)

| Published

Schliemann C, Gutbrodt KL, Kerkhoff A, Pohlen M, Wiebe S, Silling G, Angenendt L, Kessler T, Mesters RM, Giovannoni L, Schäfers M, Altvater B, Rossig C, Grünewald I, Wardelmann E, Köhler G, Neri D, Stelljes M, Berdel WE

(2015)

Cancer immunology research

, 3

(5)

547

556

doi:10.1158/2326-6066.CIR-14-0179

Research article (journal)

| Published

doi:10.1016/j.annonc.2020.08.677

Deep learning predicts therapy-relevant genetics in acute myeloid leukemia from Pappenheim-stained bone marrow smears Kockwelp, Jacqueline; Thiele, Sebastian; Bartsch, Jannis; Haalck, Lars; Gromoll, Jörg; Schlatt, Stefan; Exeler, Rita; Bleckmann, Annalen; Lenz, Georg; Wolf, Sebastian; Steffen, Björn; Berdel, Wolfgang Eduard; Schliemann, Christoph; Risse, Benjamin; Angenendt, Linus (2024) In: Blood Advances, 8(1), 70-79. doi:10.1182/bloodadvances.2023011076 Research article (journal) \| Peer reviewed \| Published
Cell Selection-based Data Reduction Pipeline for Whole Slide Image Analysis of Acute Myeloid Leukemia Kockwelp, Jacqueline; Thiele, Sebastian; Kockwelp, Pascal; Bartsch, Jannis; Schliemann, Christoph; Angenendt, Linus; Risse, Benjamin (2022) In: IEEE/CVF (eds.), The IEEE / CVF Computer Vision and Pattern Recognition Conference (CVPR). IEEE Xplore. Research article in digital collection (conference) \| Peer reviewed \| Published
563P First-in-class CD13-targeted tissue factor tTF-NGR in patients with recurrent or refractory malignant tumours: Safety and pharmacokinetic results of a phase I study Schliemann C, Gerwing M, Heinzow H, Harrach S, Schwöppe C, Wildgruber M, Hansmeier AA, Angenendt L, Berdel AF, Kessler T, Wilms C, Hartmann W, Wardelmann E, Krähling T, Heindel W, Gerss J, Schmidt H, Lenz G. Mesters R, Berdel WE (2020) In: (eds.), . (kein Verlag angegeben). Research article in edited proceedings (conference) \| Peer reviewed \| Published
First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study Schliemann C, Gerwing M, Heinzow H, Harrach S, Schwöppe C, Wildgruber M, Hansmeier AA, Angenendt L, Berdel AF, Stalmann U, Berning B, Kratz-Albers K, Middelberg-Bisping K, Wiebe S, Albring J, Wilms C, Hartmann W, Wardelmann E, Krähling T, Heindel W, Gerss J, Bormann E, Schmidt H, Lenz G, Kessler T, Mesters RM, Berdel WE (2020) In: Cancers, 12(6). doi:10.3390/cancers12061488 Research article (journal) \| Peer reviewed \| Published
NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor Brand C., Schliemann C., Ring J., Kessler T., Bäumer S., Angenendt L., Mantke V., Ross R., Hintelmann H., Spieker T., Wardelmann E., Mesters R., Berdel W., Schwöppe C. (2016) In: Oncotarget, 7(6), 6774-6789. doi:10.18632/oncotarget.6725 Research article (journal) \| Peer reviewed \| Published
A phase i dose escalation study of the triple angiokinase inhibitor nintedanib combined with low-dose cytarabine in elderly patients with acute myeloid leukemia In: . \| Peer reviewed
Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation In: , -. \| Peer reviewed
Remissions of different quality following rituximab, tocilizumab and rituximab, and allogeneic stem cell transplantation in a patient with severe idiopathic multicentric Castleman’s disease In: , -. \| Peer reviewed
Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature In: , -. \| Peer reviewed
Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation In: , -. \| Peer reviewed